Oral GT-02287 seen to safety reach adult brain cells in Phase 1 trial
An investigational treatment for Parkinson’s disease known as GT-02287 safely led to a roughly 53% increase in GCase enzyme activity, as measured in dried blood spots from treated healthy adults relative to those given a